Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

This weight-loss drug, designed for obese patients, significantly reduces breathing disruptions and offers a new treatment ...

Now, new research suggests Eli Lilly’s weight loss drug Zepbound (tirzepetide) may also support those with obstructive sleep apnea by increasing airflow and improving sleep quality. Since sleep ...

Wegovy was approved in the US as a treatment for heart disease in March, while Zepbound is expected to be given the green light as a treatment for obstructive sleep apnea, as reported by Reuters.

Wegovy was approved in the U.S. as a treatment for heart disease in March, while Zepbound is expected to be given the green light as a treatment for obstructive sleep apnea. Both drugs are sold in ...

Meanwhile, Zepbound has been shown to be a possible treatment for obstructive sleep apnea. Importantly, McGowan said weight loss isn't the only factor patients have to consider when picking a ...

Zepbound is primarily targeted at adults living with obesity or overweight who have at least one weight-relatedcomorbidity, such as hypertension, dyslipidemia, obstructive sleep apnea (OSA), or ...

obstructive sleep apnea (OSA) or cardiovascular disease. The most commonly reported side effects among those taking both Zepbound and Wegovy were mild to moderate gastrointestinal symptoms ...